Colon cancer
Stories
-
FDA approves atezolizumab plus chemotherapy for Stage III dMMR colon cancer
The FDA approved atezolizumab with a fluoropyrimidine and oxaliplatin for Stage III mismatch repair deficient colon cancer, citing a disease-free survival hazard ratio of 0.50 in 711 adults and one pediatric patient. The approval covers adults and pediatric patients two years of age and older after complete resection.